Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
    • Real Estate
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

Television pioneer dies
6 dead, 3 injured in Texas
Cause of death revealed
FBI agent carjacking arrest
Contract renewed with agency
'I won't be a dictator'
Weighs third-party run
‘DWTS’ season 32 winner
Indicted for endangerment
Welcome first baby
Air Force confirms fatality
Outrage against AI imitation
xAI seeks to raise $1 billion
US high-speed rail funding
Time's Athlete of the Year
$377M jackpot numbers
Teacher assaults student
Enlist in S. Korean military
Guilty plea in pres killing
RU rejects release proposal
Australia's economy slows
Verdugo traded to Yankees
US, Sweden defense deal
Win MLB draft lottery
Strike amid negotiations
Rays sign Chris Devenski
USWNT victory over China
Feeling 'much better'
Visits UAE, Saudi Arabia
Testify on campus antisemitism
Amazon slams Microsoft
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
5,140 results
Proactiveinvestors27d
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...
The Motley Fool19d
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials. But that drug will need ...
Reuters22d
AstraZeneca's Imfinzi plus chemoradiotherapy fail main goal of late stage trial
Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat ...
Hosted on MSN27d
AstraZeneca CEO Pascal Soriot: Treatment of cancer in the last few years has been 'remarkable'
AstraZeneca CEO Pascal Soriot discusses Q3 earnings, oncology revenue, gene therapy treatments, what's to come for the company and the U.S. supply chain. Donald Trump Being Kicked off 2024 Ballot ...
The Financial Times27d
AstraZeneca signs deal for oral obesity drug and lifts profit outlook
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca is to enter the race for a weight loss pill, working on a next-generation class of drugs that ...
Morningstar2d
AstraZeneca PLC ADR AZN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
MarketWatch27d
AstraZeneca Shares Rise After Guidance Increase
Shares of AstraZeneca rose as much as 4.2% in early trade after the company raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines after beating ...
Investing16d
AstraZeneca: Leading bank tells us why the stock is a core holding
Proactive Investors - Barclays (LON:BARC) Capital has issued an optimistic assessment of AstraZeneca PLC (LON:AZN)'s shares, recommending an 'overweight' position with a target price of £135, a ...
Proactive Investors27d
AstraZeneca faces lawsuits in High Court over ‘defective’ Covid-19 vaccine
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Get the Bing App
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices